The following table disaggregates the Company’s revenue by major source. The Company’s Royalty Revenue set forth below relates to Fampyra royalties payable under the Company’s License and Collaboration Agreement with Biogen. See Note 9 for additional information on the Company’s related payment obligation to HealthCare Royalty Partners, or HCRP, in connection with a 2017 royalty purchase agreement with HCRP.

(In thousands)	Three-month period ended September 30, 2022		Three-month period ended September 30, 2021		Nine-month period ended September 30, 2022		Nine-month period ended September 30, 2021
Revenues:
Net product revenues:
Ampyra	$	21,110	$	20,026	$	54,192	$	62,035
Inbrija U.S.		7,848		7,804		18,957		19,240
Inbrija ex-U.S.		1,006		—		2,874		—
Other		—		21		—		22
Total net product revenues		29,964		27,851		76,023		81,297
Royalty Revenue		3,047		3,605		10,573		10,807
License Revenue		500		—		500		—
Total net revenues	$	33,511	$	31,456	$	87,096	$	92,104